key: cord-0926759-w9m5g4u2 authors: Waldman, Reid A.; Creed, Marina; Sharp, Kelley; Adalsteinnson, Jonas; Imitola, Jaime; Durso, Timothy; Lu, Jun title: Letter in Reply: Toward a COVID-19 Vaccine Strategy for Pemphigus Patients on Rituximab date: 2020-10-29 journal: J Am Acad Dermatol DOI: 10.1016/j.jaad.2020.10.075 sha: fc45914a1da4df914710ca3c9e3c496034c4506e doc_id: 926759 cord_uid: w9m5g4u2 nan peripheral B-cell depletion on future COVID-19 vaccine response. Their articles highlight the 27 need for emergent study of anti-CD20 therapy's impact on COVID-19 vaccine response. Herein, 28 we review existing data surrounding vaccination of individuals receiving anti-CD20 monoclonal 29 antibodies. The effect of rituximab and other anti-CD20 monoclonal antibodies on vaccine response 31 has been studied for inactivated vaccines including seasonal influenza, hepatitis B, tetanus, 32 shingles, pneumococcus, and Haemophilus influenza B. 1,2 These studies suggest that rituximab 33 recipients mount attenuated, yet meaningful vaccine responses. 1 Additionally, these studies While vaccine response may be attenuated and may occur at lower rates in rituximab recipients, 63 vaccine response can be quantified with titers which may be helpful for guiding decisions to 64 revaccinate patients following humoral immune reconstitution (~6-9 months after rituximab COVID-19 vaccine-readiness for anti-CD20-73 depleting therapy in autoimmune diseases Could anti-CD20 therapy jeopardise the efficacy of 76 a SARS-CoV-2 vaccine? Immunizations 78 in immunocompromised patients: a guide for dermatologists Effect of ocrelizumab on vaccine responses in 81 patients with multiple sclerosis: The VELOCE study mRNA vaccines -a new era in vaccinology